In vivo imaging demonstrated that 18F-AlF-NOTA-ZPD-L1 effectively distinguished between PD-L1 high-expressing U87-MGvIII tumors and PD-L1-negative H292PD-L1KO tumors, providing high-contrast brain tumor images within one hour postinjection. This evidence concerns the gene CD274 and brain neoplasm.